Regenerative medicines are headed for people with Parkinson’s disease or severe heart failure — but researchers are concerned about minimal clinical-trial data.

After treatment, the mice’s memories were essentially shunted back into a younger state. The researchers found that reprogrammed engrams displayed molecular behavior of more youthful cells. Using a ...

Chinese researchers report the first reversal of type 2 diabetes using stem cell therapy, restoring natural insulin ...

Gilead Sciences is buying blood cancer drug developer Arcellx for up to $7.8bn as pharmaceutical groups rush to acquire ...

A vaccine usually trains your immune system to recognize one target. Here, the target is basically “anything that doesn’t ...

MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today ...

The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently, the ...

Researchers found that activating the STING pathway with an experimental agonist reduced meningioma growth, triggered ...

Stanford Medicine researchers have developed an experimental nasal vaccine that shielded mouse lungs for at least three months against a striking range of respiratory threats, from SARS-CoV-2 and ...

Review Suggests Gut Microbiome Influences Response to GLP-1 Drugs What if the reason some people lose more weight—or see better blood sugar control—on ...

Gilead is now waiting upon the FDA’s approval of anito-cel, Arcellx’s lead candidate, slated for December 2026.

A single exposure to a common agricultural fungicide may echo through the generations far longer than previously understood – potentially affecting the health of descendants 20 generations later.